Contracts

Information is courtesy of the Office of Sponsored Projects. Each listing includes the faculty member’s name and school(s) appointments at The University of Texas Health Science Center at Houston, contracting agency, contract amount and title.

Vernon Anderson, Medical School (MS), Millenium Pharmaceuticals Inc., $68,702, A Randomized Trial to Evaluate the Relative Protection Against Post-PCI Microvascular Dysfunctin and Post-PCI Ischemia among Anti-Platelet and Anti-Thrombotic Agents.

Roberto Arduino, MS, University of Minnesota, $74,600, A Phase III Multicenter Randomized Study of the Biological and Clinical Efficacy of Subcutaneous Recombinant, Human Interleukin-2 in HIV-infected Patients with Low CD4+ Counts Under Active Antiretrovial Therapy (the SILCAAT Trial).

Eric Boerwinkle, School of Public Health (SPH) and Graduate School of Biomedical Sciences (GSBS), TexGen Research, $10,000, Premature Myocardial Infarction Protocol.

Staley Brod, MS and GSBS, Biogen Inc., $240,200, A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Design Safety Study of Natalizumab in Combination with Glatiramer Acetate (GA) in Subjects with Relapsing-Remitting Multiple Sclerosis (MS).

Giuseppe Colasurdo, MS, Merck & Co. Inc., $35,500, A Randomized, Two-Period, Multicenter, Double Blind, Parallel-Group Study Comparing the Effects of Two Doses of Montelukast Granules and Placebo in the Treatment of Respiratory Symptoms Associated with Respiratory Syncytial Virus-Induced Bronchiolitis in Children Aged 6 to 18 Months.

Ralf Gebhard, MS, Merck & Co. Inc., $74,118, A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Safety, Tolerability and Efficacy of Two Doses of Aprepitant for the Prevention of Postoperative Nausea and Vomiting.

Carin Hagberg, Medical School (MS), Portex Inc., $27,599, A Randomized Clinical Comparison of the Portex Soft Seal Laryngeal Mask and the Intravent Unique Single Use Laryngeal Mask in Adult Patients; and Ambu A/S, $31,465, Combined International Multi-Centre Phase I and II Study Verifying the Safety and Performance of the Ambu A/S Laryngeal Mask for Patients Undergoing Routine Anesthesia.

Adelaide Hebert, MS, TARO Pharmaceuticals USA Inc., $66,000, A Multi-Center, Double-Blind Study of Desoximetasone 0.25% Ointment and Tacrolimus 0.1% Ointment in the Treatment of Atopic Dermatitis.

Jary M. Lesser, MS, Eisai/Covance, $71,370, An Open-Label, Multicenter, One-Year Extension of the Evaluation of the Safety of Donepezil Hydorchloride (E2020 Aricept) in Patients with Dementia Associated with Cerebrovascular Disease.

David Mercer, MS, Wyeth Pharmaceuticals Inc., $59,850, A Multicenter, Double-Blind, Randomized Comparison Study of the Efficacy and Safety of Tigecycline to Imipenem/Cilastatin to Treat Complicated Intra-Abdominal Infections in Hospitalized Subjects; Wyeth Pharmaceuticals Inc., $77,000, A Multicenter, Randomized, Double-Blind Comparison of the Safety and Efficacy of Tigecycline with those of Vancomycin with Aztreonam to Treat Complicated Skin and Skin Structure Infections in Hospitalized Patients; and Merck & Co. Inc., $51,024, A Prospective, Multicenter, Double-Blind with In-House Blinding, Randomized, Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Ertapenem Sodium Versus Piperacillin-Tazobactam in the Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults.

Barbara Murray, MS and GSBS, Daiichi Pharmaceutical Co. Ltd., $28,600, Assessment of in vivo Activity of Sitafloxacin in a Mouse Peritonitis Model. John Powers, Dental Branch and GSBS, Tokuyama Dental Corp., $30,000, Improved Dental Materials.